Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Bausch Health Companies Inc. | d583672d8k.htm |
| EX-3.3 - EX-3.3 - Bausch Health Companies Inc. | d583672dex33.htm |
| EX-3.1 - EX-3.1 - Bausch Health Companies Inc. | d583672dex31.htm |
| EX-3.2 - EX-3.2 - Bausch Health Companies Inc. | d583672dex32.htm |
Exhibit 99.1
International Headquarters
2150 St. Elzéar Blvd. West
Laval, Quebec H7L 4A8
Phone: 514.744.6792
Fax: 514.744.6272
Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com
VALEANT PHARMACEUTICALS ANNOUNCES CONTINUANCE
Laval, Quebec — August 9, 2013 — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that, effective August 9, 2013, it has continued from the federal jurisdiction of Canada to the Province of British Columbia (the “Continuance”) pursuant to a resolution passed by shareholders of the Company at the annual meeting held May 21, 2013. The Continuance results in the Company becoming subject to all of the provisions of the British Columbia Business Corporations Act.
About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology and branded generics. More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.
###